Alpha Tau Completes Enrollment in IMPACT Pancreatic Cancer Study, Expanding from 12 to 48 Patients
DRTS has more than doubled off its 52-week low of $3.18.
Summary
Alpha Tau completed enrollment in its IMPACT pancreatic cancer pilot study with 48 patients, up from an original 12-patient design, following three expansions driven by strong demand. Initial data is targeted for early 2027 to inform a planned pivotal study.
Key Events · Product Development and Regulatory · DRTS
-
IMPACT Enrollment Completed at 48 Patients
Alpha Tau completed enrollment in its multicenter IMPACT pancreatic cancer pilot study with 48 patients, up from an original 12-patient design after three expansions driven by strong demand from patients and clinicians.
-
Study Design and Expansion
IMPACT evaluates intratumoral Alpha DaRT in combination with first-line chemotherapy (mFOLFIRINOX or gemcitabine + nab-paclitaxel) for newly diagnosed unresectable pancreatic cancer, conducted at 10 centers in the U.S., Canada, and Israel.
-
Data Release Targeted for Early 2027
Initial data from IMPACT is targeted for early 2027 and is intended to inform the design of a planned pivotal study.
-
Global Pancreatic Cancer Program
IMPACT anchors a global pancreatic cancer program that also includes the ACAPELLA trial in France and a study at the University of Verona's Pancreas Institute.
Analysis · DRTS · Industrial Applications And Services
Alpha Tau completed enrollment in its IMPACT pancreatic cancer pilot study, expanding from an original 12-patient design to 48 patients across three expansions driven by strong demand. The study evaluates Alpha DaRT as a one-time add-on to first-line chemotherapy for newly diagnosed unresectable pancreatic cancer. Data is targeted for early 2027 and will inform a planned pivotal study. This milestone validates the safety profile observed in earlier Israeli and Canadian studies and positions Alpha Tau to advance a global pancreatic cancer program that also includes the ACAPELLA trial in France and a study at the University of Verona.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRTS was trading at $14.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.18 to $15.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.